Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Sophia Genetics Sa (SOPH)

Sophia Genetics Sa (SOPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 307,502
  • Shares Outstanding, K 68,486
  • Annual Sales, $ 77,270 K
  • Annual Income, $ -79,000 K
  • EBIT $ -71 M
  • EBITDA $ -61 M
  • 60-Month Beta 1.13
  • Price/Sales 3.95
  • Price/Cash Flow N/A
  • Price/Book 6.32

Options Overview Details

View History
  • Implied Volatility 150.58% (+10.27%)
  • Historical Volatility 52.34%
  • IV Percentile 63%
  • IV Rank 15.15%
  • IV High 674.61% on 04/04/25
  • IV Low 57.03% on 09/04/25
  • Expected Move (DTE 9) 0.89 (19.88%)
  • Put/Call Vol Ratio 1.25
  • Today's Volume 18
  • Volume Avg (30-Day) 25
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 2,261
  • Open Int (30-Day) 2,365
  • Expected Range 3.60 to 5.38

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.28
  • Growth Rate Est. (year over year) +356,885.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.01 +12.11%
on 03/04/26
5.06 -11.26%
on 02/11/26
-0.29 (-6.07%)
since 02/10/26
3-Month
4.01 +12.11%
on 03/04/26
5.70 -21.23%
on 01/22/26
-0.16 (-3.44%)
since 12/10/25
52-Week
2.58 +74.03%
on 04/21/25
5.70 -21.23%
on 01/22/26
+1.28 (+39.88%)
since 03/10/25

Most Recent Stories

More News
SOPHiA GENETICS Reports Fourth Quarter and Full Year 2025 Results

BOSTON and ROLLE, Switzerland , March 3, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the fourth quarter...

SOPH : 4.49 (+0.67%)
SOPHiA GENETICS to Present at the 46th Annual TD Cowen Health Care Conference

BOSTON and ROLLE, Switzerland , Feb. 25, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today announced that leadership will present at TD...

SOPH : 4.49 (+0.67%)
SOPHiA GENETICS to Announce Financial Results for Fourth Quarter and Full Year 2025 on March 3, 2026

BOSTON and ROLLE, Switzerland , Feb. 17, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today announced it will release its financial results...

SOPH : 4.49 (+0.67%)
SOPHiA GENETICS Announces Major Expansion in the United States with the Signing of Two Major Integrated Health Systems

BOSTON and ROLLE, Switzerland , Feb. 10, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, today announced the addition of two of the largest...

SOPH : 4.49 (+0.67%)
SOPHiA GENETICS Provides Preliminary Fourth Quarter and Full Year 2025 Financial Results, Initiates 2026 Guidance, and Announces Executive Transition Plan

The Company finishes 2025 with strong Q4 performance, expects 20-22% revenue growth in 2026, and promotes Ross Muken to CEO

SOPH : 4.49 (+0.67%)
SOPHiA GENETICS and MD Anderson Announce Strategic Collaboration to Accelerate AI-Driven Precision Oncology

BOSTON and HOUSTON , Jan. 7, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, and The University of Texas MD Anderson Cancer Center today announced...

SOPH : 4.49 (+0.67%)
SOPHiA GENETICS and Complete Genomics Integrate Sequencing and AI Analytics to Accelerate Adoption of Precision Medicine

BOSTON , Nov. 11, 2025 /PRNewswire/ -- Complete Genomics , a leading innovator in genomic sequencing, today announced a collaboration with SOPHiA GENETICS (NASDAQ: SOPH), a global leader...

SOPH : 4.49 (+0.67%)
SOPHiA GENETICS and Element Biosciences Unite Sequencing Power and AI Analytics to Accelerate Global Research In Precision Medicine

BOSTON and SAN DIEGO , Nov. 11, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, and Element Biosciences, Inc., a biology company transforming...

SOPH : 4.49 (+0.67%)
SOPHiA GENETICS and Element Biosciences Unite Sequencing Power and AI Analytics to Accelerate Global Research In Precision Medicine

BOSTON and SAN DIEGO , Nov. 11, 2025 /CNW/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, and Element Biosciences, Inc., a biology company transforming the pace...

SOPH : 4.49 (+0.67%)
SOPHiA GENETICS Reports Third Quarter 2025 Results and Increases 2025 Revenue Guidance

BOSTON and ROLLE, Switzerland , Nov. 4, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the third quarter...

SOPH : 4.49 (+0.67%)

Business Summary

SOPHiA GENETICS SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM(TM) Platform, a cloud-based SaaS platform capable of analyzing data and generating insights...

See More

Key Turning Points

3rd Resistance Point 4.88
2nd Resistance Point 4.76
1st Resistance Point 4.62
Last Price 4.49
1st Support Level 4.37
2nd Support Level 4.25
3rd Support Level 4.12

See More

52-Week High 5.70
Fibonacci 61.8% 4.51
Last Price 4.49
Fibonacci 50% 4.14
Fibonacci 38.2% 3.77
52-Week Low 2.58

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar